- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04113551
A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
January 21, 2020 updated by: Janssen Research & Development, LLC
Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan: A Retrospective Cohort Study of Label Compliance
The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
17418
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Titusville, New Jersey, United States, 08560
- Janssen Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
The study population will comprise of population (participants with attention deficit/hyperactivity disorder [ADHD]) described in the Japan Medical Data Center (JMDC) database which has data available through 1 January 2005 to 30 September 2018.
Description
Inclusion Criteria:
- Participants have been in the database for greater than or equal to (>=) 30 days
- Have received, between 1 January, 2013 and 30 September, 2018, a prescription for Concerta, Ritalin, Atomoxetine (ATO) or Guanfacine (GFC)
Exclusion Criteria:
- Participants who received an unspecified Methylphenidate (MPH) formulation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort T1: Methylphenidate (MPH) (Concerta)
Analysis of data will be performed for participants who have had first exposure of MPH (Concerta) and who were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
|
MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from Japan medical data center (JDMC) database.
|
Cohort T2: MPH (Ritalin)
Analysis of data will be performed for participants who have had first exposure of MPH (Ritalin) and who were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
|
MPH (Ritalin) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
Cohort T3: MPH (Concerta and Ritalin)
Analysis of data will be performed for participants who have had exposure to Concerta and Ritalin during the time in the cohort between 1 January 2013 and 30 September 2018 and has continuous observation of at least 30 days prior to the exposures.
|
MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from Japan medical data center (JDMC) database.
MPH (Ritalin) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
Cohort T4: Atomoxetine (ATO)
Analysis of data will be performed for participants who have had first exposure of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
|
Atomoxetine (ATO) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
Cohort T5: Guanfacine (GFC)
Analysis of data will be performed for participants who have had first exposure of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
|
Guanfacine (GFC) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC
Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin), ATO, or GFC first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
|
MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from Japan medical data center (JDMC) database.
MPH (Ritalin) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
Atomoxetine (ATO) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
Guanfacine (GFC) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
Cohort T7: MPH (Concerta or Ritalin)
Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin) first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior.
These are the first exposure to any MPH among the participants with who had some exposure to MPH.
|
MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from Japan medical data center (JDMC) database.
MPH (Ritalin) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
Cohort T8: MPH (Concerta) All Exposures
Analysis of data will be performed for participants who have had all exposures of MPH (Concerta) and were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
|
MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from Japan medical data center (JDMC) database.
|
Cohort T9: MPH (Ritalin) All Exposures
Analysis of data will be performed for participants who have had all exposures of MPH (Ritalin) and were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
|
MPH (Ritalin) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
Cohort T10: ATO All Exposures
Analysis of data will be performed for participants who have had all exposures of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
|
Atomoxetine (ATO) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
Cohort T11: GFC All Exposures
Analysis of data will be performed for participants who have had all exposures of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
|
Guanfacine (GFC) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures
Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin), ATO, or GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
|
MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from Japan medical data center (JDMC) database.
MPH (Ritalin) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
Atomoxetine (ATO) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
Guanfacine (GFC) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
Cohort T13: MPH (Concerta or Ritalin) All Exposures
Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta or Ritalin).
|
MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from Japan medical data center (JDMC) database.
MPH (Ritalin) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
Cohort T14: MPH (Concerta and Ritalin) All Exposures
Analysis of data will be performed for participants who have had all exposures of MPH (Concerta and Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta) during the study period and to an exposure to MPH (Ritalin) during the study period.
|
MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from Japan medical data center (JDMC) database.
MPH (Ritalin) is approved for the indication of ADHD in Japan.
This is a non-interventional study and no drug will be given as part of this study.
Analysis will be performed from data taken from JDMC database.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Stratified on Age, Sex, and Medication
Time Frame: Up to 5.8 years
|
The percentage of participants stratified on age, sex, and medication (Methylphenidate [MPH] [Concerta], MPH [Ritalin], Atomoxetine [ATO], Guanfacine [GFC]) will be reported.
The data will be taken from Japan Medical Data Center (JMDC) database for analysis.
|
Up to 5.8 years
|
Percentage of the Specialty of the Department of the First Prescriber who Prescribe MPH (Concerta), MPH (Ritalin), ATO, or GFC
Time Frame: Up to 5.8 years
|
The percentage of specialty of the department of the first prescriber for each first dispensing of each study medication will be reported.
The data will be taken from JMDC database for analysis.
|
Up to 5.8 years
|
Percentage of Participants whose First Prescription for MPH (Concerta), MPH (Ritalin), ATO, or GFC was Associated with an On-label Diagnosis
Time Frame: Up to 5.8 years
|
The percentage of participants whose first prescription for MPH (Concerta), MPH (Ritalin), ATO, or GFC was associated with an on-label diagnosis, that is, a diagnosis of Attention Deficit Disorder with Hyperactivity (ADHD) for MPH (Concerta), ATO or GFC; or a diagnosis of narcolepsy for MPH (Ritalin) will be reported.
The data will be taken from JMDC database for analysis.
|
Up to 5.8 years
|
Percentage of Participants who Received More than Maximum Recommended Dose of MPH (Concerta), MPH (Ritalin), Methylphenidate (Concerta and Ritalin), ATO, or GFC
Time Frame: Up to 5.8 years
|
The percentage of participants who received more than the maximum recommended dose of MPH (Concerta), MPH (Ritalin), Methylphenidate (Concerta and Ritalin), ATO, or GFC will be reported.
The data will be taken from JMDC database for analysis.
|
Up to 5.8 years
|
Percentage of Participants not Meeting Age Criteria at the Time of Receiving Medication
Time Frame: Up to 5.8 years
|
Percentage of participants who at the time of receiving the medication were outside the approved age range will be reported.
The data will be taken from JMDC database for analysis.
|
Up to 5.8 years
|
Percentage of Participants not Meeting Medication Criteria at the Time of Receiving Medication
Time Frame: Up to 5.8 years
|
Percentage of participants who at the time of receiving the medication had other contraindications will be reported.
The data will be taken from JMDC database for analysis.
|
Up to 5.8 years
|
Percentage of Participants whose Prescriptions were Consistent with all Aspects of the Label that was Current at the Time of the Prescription
Time Frame: Up to 5.8 years
|
Percentage of participants whose prescriptions were consistent with all aspects of the label that was current at the time of the prescription will be reported.
The data will be taken from JMDC database for analysis.
|
Up to 5.8 years
|
Percentage of Participants with Shopping Behavior as a Marker of Misuse of Medications
Time Frame: Up to 5.8 years
|
Percentage of participants whose use pattern of MPH (Concerta), MPH (Ritalin), MPH (Concerta and Ritalin) or ATO included prescriptions from three or more departments within any 18-month period will be reported.
This describes "shopping behavior", which is a marker for misuse or abuse of medications.
The data will be taken from JMDC database for analysis.
|
Up to 5.8 years
|
Time Trends in Percentage of Participants Compliant with all Label Requirements
Time Frame: Up to 5.8 years
|
The time trends in the percentage of participants whose prescriptions complied with all requirements of the label for MPH (Concerta), MPH (Ritalin), MPH (Concerta and Ritalin), ATO, and GFC will be reported.
The data will be taken from JMDC database for analysis.
|
Up to 5.8 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2019
Primary Completion (Actual)
January 10, 2020
Study Completion (Actual)
January 10, 2020
Study Registration Dates
First Submitted
October 1, 2019
First Submitted That Met QC Criteria
October 1, 2019
First Posted (Actual)
October 2, 2019
Study Record Updates
Last Update Posted (Actual)
January 22, 2020
Last Update Submitted That Met QC Criteria
January 21, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Adrenergic Uptake Inhibitors
- Methylphenidate
- Atomoxetine Hydrochloride
- Guanfacine
Other Study ID Numbers
- CR108692
- PCSESP001604 (Other Identifier: Janssen Research and Development, LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Disorder With Hyperactivity
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Rabin Medical CenterNG Solutions LtdRecruitingADHD - Attention Deficit Disorder With HyperactivityIsrael
-
Karolinska InstitutetCompletedAttention Deficit Disorder With Hyperactivity (ADHD)Sweden
-
University of PennsylvaniaCompletedAttention Deficit Disorder With Hyperactivity (ADHD)United States
-
Fondation LenvalCompletedAttention Deficit Disorder With Hyperactivity | Attention Deficit Disorder Without HyperactivityFrance
-
Clinical and Translational Genome Research Institute...Children's Specialized HospitalTerminatedAttention Deficit Disorders With HyperactivityUnited States
-
Massachusetts General HospitalRecruitingAttention Deficit Disorder With Hyperactivity | Attention Deficit DisorderUnited States
-
Nemours Children's ClinicCompletedAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit DisorderUnited States
-
New River PharmaceuticalsShireCompletedAttention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersUnited States
Clinical Trials on MPH (Concerta)
-
Tri-Service General HospitalMinistry of Science and Technology, TaiwanCompletedDisruptive Mood Dysregulation Disorder
-
Massachusetts General HospitalOrtho-McNeil Janssen Scientific Affairs, LLCCompleted
-
Memorial Health University Medical CenterCompleted
-
Ortho-McNeil Janssen Scientific Affairs, LLCCompletedAttention Deficit Disorder With Hyperactivity
-
Children's Hospital Medical Center, CincinnatiSeattle Children's HospitalCompleted
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Dependence | Methamphetamine AbuseUnited States, Canada
-
Dana-Farber Cancer InstituteBoston Children's HospitalTerminated
-
Loewenstein HospitalTel Aviv University; Wingate InstituteRecruiting
-
Grupo Español de Rehabilitación MultimodalUniversidad de Zaragoza; Aragon Health Science InstituteRecruitingPostoperative SepsisSpain
-
Peking UniversityCompletedAttention Deficit Hyperactivity DisorderChina